Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia.
Roszymah HamzahNurasyikin YusofNor Rafeah TumianSuria Abdul AzizNur Syahida Mohammad BasriTze Shin LeongKim Wah HoVeena SelvaratnamSen Mui TanSiti Afiqah Muhamad JamilPublished in: Journal of blood medicine (2022)
This study confirms the epidemiology of ITP is comparable with worldwide studies. Our incidence is high in the female, Malay ethnicity, primary ITP and events of cutaneous bleeding at ITP onset with 18-29 years predominance age group for both genders. The frequency of persistent and chronic ITP is inconsistent with published literature. Corticosteroids and immunotherapies are the most prescribed first-line and second-line pharmacological treatments. Thrombopoietin receptor agonist medications (TPO-RAs) usage is restricted and splenectomy is uncommon. Our mortality rate is similar but ITP related bleeding death is fourth-fold lower than previous studies. Mortality risks of our ITP patients include age ≥60 years, male, severe bleeding at presentation, CCI≥1 and secondary ITP.
Keyphrases
- newly diagnosed
- risk factors
- cardiovascular events
- atrial fibrillation
- end stage renal disease
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- neuropathic pain
- type diabetes
- risk assessment
- prognostic factors
- drug induced
- case control
- human health
- patient reported outcomes
- climate change
- wild type